While T-DM1 is effective in HER2-positive tumors, T-DXd’s broader applicability to HER2-low cancers provides a significant advancement, particularly for patients with reduced HER2 expression or those who have developed resistance to earlier HER2-targeted therapies [15,18]. This evidence concerns the gene ERBB2 and cancer.